415 related articles for article (PubMed ID: 10658525)
61. [Irinotecan plus fuorouracil/leucovorin (FOLFIRI) as a second line chemotherapy for refractory or metastatic colorectal cancer].
Li J; Xu JM; Li J; Zhang XD; Bai Y; Chu YP; Wang YH; Liu DQ; Jin ML; Shen L
Zhonghua Zhong Liu Za Zhi; 2008 Mar; 30(3):225-7. PubMed ID: 18756942
[TBL] [Abstract][Full Text] [Related]
62. Oxaliplatin added to simplified bimonthly low-dose leucovorin and 5-FU for pretreated advanced colorectal cancer is effective and not affected by different previous 5-FU regimens.
Hsieh RK; Chao TY; Chen WS; Yang TS; Chen LT; Chen PM; Liu JH
Cancer Invest; 2004; 22(2):171-9. PubMed ID: 15199598
[TBL] [Abstract][Full Text] [Related]
63. Phase I study of a weekly schedule of irinotecan, high-dose leucovorin, and infusional fluorouracil as first-line chemotherapy in patients with advanced colorectal cancer.
Vanhoefer U; Harstrick A; Köhne CH; Achterrath W; Rustum YM; Seeber S; Wilke H
J Clin Oncol; 1999 Mar; 17(3):907-13. PubMed ID: 10071283
[TBL] [Abstract][Full Text] [Related]
64. A dose-finding study of irinotecan (CPT-11) plus a four-day continuous 5-fluorouracil infusion in advanced colorectal cancer.
Kakolyris S; Souglakos J; Kouroussis C; Androulakis N; Mavroudis D; Kalbakis K; Kotsakis A; Vardakis N; Koukourakis M; Romanos J; Georgoulias V
Oncology; 2001; 60(3):207-13. PubMed ID: 11340371
[TBL] [Abstract][Full Text] [Related]
65. Phase III randomized trial of FOLFIRI versus FOLFOX4 in the treatment of advanced colorectal cancer: a multicenter study of the Gruppo Oncologico Dell'Italia Meridionale.
Colucci G; Gebbia V; Paoletti G; Giuliani F; Caruso M; Gebbia N; Cartenì G; Agostara B; Pezzella G; Manzione L; Borsellino N; Misino A; Romito S; Durini E; Cordio S; Di Seri M; Lopez M; Maiello E; Montemurro S; Cramarossa A; Lorusso V; Di Bisceglie M; Chiarenza M; Valerio MR; Guida T; Leonardi V; Pisconti S; Rosati G; Carrozza F; Nettis G; Valdesi M; Filippelli G; Fortunato S; Mancarella S; Brunetti C;
J Clin Oncol; 2005 Aug; 23(22):4866-75. PubMed ID: 15939922
[TBL] [Abstract][Full Text] [Related]
66. Salvage chemotherapy with biweekly irinotecan, plus 5-fluorouracil and leucovorin in patients with advanced gastric cancer previously treated with fluoropyrimidine, platinum, and taxane.
Sym SJ; Ryu MH; Lee JL; Chang HM; Kim TW; Lee SS; Lee JS; Kang YK
Am J Clin Oncol; 2008 Apr; 31(2):151-6. PubMed ID: 18391599
[TBL] [Abstract][Full Text] [Related]
67. Bimonthly high dose leucovorin and 5-fluorouracil 48-hour infusion with interferon-alpha-2a in patients with advanced colorectal carcinoma. Groupe d'Etude et de Recherche sur les Cancers de l'Ovaire et Digestifs (GERCOD).
Tournigand C; Louvet C; de Gramont A; Lucchi E; Seitz JF; Mal F; Raymond E; Cady J; Carola E; Krulik M
Cancer; 1997 Mar; 79(6):1094-9. PubMed ID: 9070485
[TBL] [Abstract][Full Text] [Related]
68. Irinotecan plus weekly 5-fluorouracil and leucovorin as salvage treatment for patients with metastatic colorectal cancer: a phase II trial.
Souglakos J; Vardakis N; Androulakis N; Kakolyris S; Kourousis C; Mavroudis D; Pallis A; Agelaki S; Kalbakis K; Georgoulias V
Dig Dis; 2007; 25(1):100-5. PubMed ID: 17384515
[TBL] [Abstract][Full Text] [Related]
69. Irinotecan plus fluorouracil/leucovorin for metastatic colorectal cancer: a new survival standard.
Saltz LB; Douillard JY; Pirotta N; Alakl M; Gruia G; Awad L; Elfring GL; Locker PK; Miller LL
Oncologist; 2001; 6(1):81-91. PubMed ID: 11161231
[TBL] [Abstract][Full Text] [Related]
70. Phase I and pharmacokinetic study of two different schedules of oxaliplatin, irinotecan, Fluorouracil, and leucovorin in patients with solid tumors.
Goetz MP; Erlichman C; Windebank AJ; Reid JM; Sloan JA; Atherton P; Adjei AA; Rubin J; Pitot H; Galanis E; Ames MM; Goldberg RM
J Clin Oncol; 2003 Oct; 21(20):3761-9. PubMed ID: 12963697
[TBL] [Abstract][Full Text] [Related]
71. Single-agent irinotecan or FOLFIRI as second-line chemotherapy for advanced colorectal cancer; results of a randomised phase II study (DaVINCI) and meta-analysis [corrected].
Clarke SJ; Yip S; Brown C; van Hazel GA; Ransom DT; Goldstein D; Jeffrey GM; Tebbutt NC; Buck M; Lowenthal RM; Boland A; Gebski V; Zalcberg J; Simes RJ;
Eur J Cancer; 2011 Aug; 47(12):1826-36. PubMed ID: 21665462
[TBL] [Abstract][Full Text] [Related]
72. Biweekly chemotherapy with oxaliplatin, irinotecan, infusional Fluorouracil, and leucovorin: a pilot study in patients with metastatic colorectal cancer.
Falcone A; Masi G; Allegrini G; Danesi R; Pfanner E; Brunetti IM; Di Paolo A; Cupini S; Del Tacca M; Conte P
J Clin Oncol; 2002 Oct; 20(19):4006-14. PubMed ID: 12351598
[TBL] [Abstract][Full Text] [Related]
73. A phase I trial of CPT-11 in combination with 5-fluorouracil plus leucovorin chemotherapy for patients with metastatic colorectal cancer.
Yamaguchi Y; Minami K; Kawabuchi Y; Emi M
Hepatogastroenterology; 2006; 53(68):201-5. PubMed ID: 16608024
[TBL] [Abstract][Full Text] [Related]
74. Use of the folinic acid/5-fluorouracil/irinotecan (FOLFIRI 1) regimen in elderly patients as a first-line treatment for metastatic colorectal cancer: a Phase II study.
François E; Berdah JF; Chamorey E; Lesbats G; Teissier E; Codoul JF; Badetti JL; Hébert C; Mari V
Cancer Chemother Pharmacol; 2008 Nov; 62(6):931-6. PubMed ID: 18273618
[TBL] [Abstract][Full Text] [Related]
75. Irinotecan combined with 5-fluorouracil and leucovorin third-line chemotherapy after failure of fluoropyrimidine, platinum, and taxane in gastric cancer: treatment outcomes and a prognostic model to predict survival.
Kang EJ; Im SA; Oh DY; Han SW; Kim JS; Choi IS; Kim JW; Kim YJ; Kim JH; Kim TY; Lee JS; Bang YJ; Lee KW
Gastric Cancer; 2013 Oct; 16(4):581-9. PubMed ID: 23266882
[TBL] [Abstract][Full Text] [Related]
76. Phase I/II study of first-line irinotecan combined with 5-fluorouracil and folinic acid Mayo Clinic schedule in patients with advanced colorectal cancer.
Kuehr T; Ruff P; Rapoport BL; Falk S; Daniel F; Jacobs C; Davidson N; Thaler J; Boussard B; Carmichael J
BMC Cancer; 2004 Jul; 4():36. PubMed ID: 15257756
[TBL] [Abstract][Full Text] [Related]
77. FOLFIRI.3, a new regimen combining 5-fluorouracil, folinic acid and irinotecan, for advanced pancreatic cancer: results of an Association des Gastro-Enterologues Oncologues (Gastroenterologist Oncologist Association) multicenter phase II study.
Taïeb J; Lecomte T; Aparicio T; Asnacios A; Mansourbakht T; Artru P; Fallik D; Spano JP; Landi B; Lledo G; Desrame J
Ann Oncol; 2007 Mar; 18(3):498-503. PubMed ID: 17158774
[TBL] [Abstract][Full Text] [Related]
78. Phase II study of irinotecan with bolus and high dose infusional 5-FU and folinic acid (modified de Gramont) for first or second line treatment of advanced or metastatic colorectal cancer.
Leonard P; Seymour MT; James R; Hochhauser D; Ledermann JA
Br J Cancer; 2002 Nov; 87(11):1216-20. PubMed ID: 12439708
[TBL] [Abstract][Full Text] [Related]
79. Sequential administration of 5-fluorouracil (5FU)/leucovorin (LV) followed by irinotecan (CPT-11) at relapse versus CPT-11 followed by 5-FU/LV in advanced colorectal carcinoma. A phase III randomized study.
Tsavaris N; Kosmas C; Skopelitis H; Papadoniou N; Polyzos A; Zografos G; Adoniou E; Gryniatsos J; Felekouras E; Zacharakis M; Sigala F; Bacoyiannis C; Papastratis G; Papalambros E
Chemotherapy; 2007; 53(4):282-91. PubMed ID: 17496414
[TBL] [Abstract][Full Text] [Related]
80. PEPCOL: a GERCOR randomized phase II study of nanoliposomal irinotecan PEP02 (MM-398) or irinotecan with leucovorin/5-fluorouracil as second-line therapy in metastatic colorectal cancer.
Chibaudel B; Maindrault-Gœbel F; Bachet JB; Louvet C; Khalil A; Dupuis O; Hammel P; Garcia ML; Bennamoun M; Brusquant D; Tournigand C; André T; Arbaud C; Larsen AK; Wang YW; Yeh CG; Bonnetain F; de Gramont A
Cancer Med; 2016 Apr; 5(4):676-83. PubMed ID: 26806397
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
